Exploring Selective β2-AR Antagonism: Important Clinical Findings on Asthma Trial Results
A recently completed clinical trial has provided new insights into the potential use of selective β2-adrenergic receptor (β2-AR) antagonism with […]
Groundbreaking Insights: ESWT and Home Exercises for Patellofemoral Pain Syndrome
In an important step for managing patellofemoral pain syndrome (PFPS), a clinical trial evaluating the combined use of extracorporeal shock
FDA Unveils TEMPO Pilot Program to Boost Safe Access to Digital Health Tools for Chronic Diseases
The U.S. Food and Drug Administration (FDA) has announced a groundbreaking initiative aimed at improving access to digital health technologies.
FDA Introduces TEMPO Digital Health Pilot to Improve Chronic Disease Care Access
The U.S. Food and Drug Administration (FDA) unveiled the Technology-Enabled Meaningful Patient Outcomes (TEMPO) for Digital Health Devices Pilot on
Triana Secures $120M Series B as Protego Adds $130M, Marking Major December Biotech Fundraises
Meta description: Triana Biomedicines raises $120 million in a Series B while Protego Biopharma secures $130 million, signaling strong December
Swissmedic Launches 2025 Oversight Fee Self-Declaration: Key Details for Medical Device Professionals
Swissmedic, Switzerland’s authority for therapeutic products, has announced the self-declaration deadline for the 2025 oversight fee. Medical device manufacturers, clinical
Swissmedic Expands Therapeutic Indication for Jemperli®
On December 5, 2025, Swissmedic announced an extension to the therapeutic indication for Jemperli®, emphasizing its crucial role in the
Swissmedic Announces New Extension of Indication for Tevimbra®
On December 5, 2025, Swissmedic published an update regarding the therapeutic indication of Tevimbra®. This regulatory decision expands the scope
Swissmedic Expands Tevimbra® Indication: Key Regulatory Update
Swissmedic, the Swiss Agency for Therapeutic Products, has officially announced the approval of an extended therapeutic indication for Tevimbra®. This
FDA Grants Conditional Approval for Cattle Treatment Addressing New World Screwworm and Fever Ticks
The U.S. Food and Drug Administration (FDA) has granted conditional approval for Exzolt Cattle-CA1 (fluralaner), a topical solution designed to